This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Theraloc (EU), TheraCIM h-R3, OSAG101, DE-766
Description: A humanized anti-EGFR antibody, TheraCIM h-R3 is similar to ImClone's Erbitux and Abgenix's ABX-EGF.
Deal Structure: Nimotuzumab was originally developed by YM BioSciences.
YM and Oncoscience
In November 2003, YM and Oncoscience signed an agreement giving Oncoscience all rights and expenses for the development and regulatory process in Europe. Under the terms of the agreement, YMs subsidiary CIMYM will receive a minimum US$30 million as ashare of any sublicensing fees and as a premium royalty on initial sales. CIMYM will also receive anescalating royalty on all sales of the product.
CIMYM and Kuhnil
YM BioSciences' subsidiary, CIMYM Inc., partnered with Kuhnil Pharmaceutical Company of Seoul, Korea in June 2005 to expand the development program for TheraCIM-hR3 for the specific population of patients with non-small cell lung cancer (NSCLC).
Kuhnil will join the Joint Development Team, already comprised of YM, Oncoscience A.G. and CIMAB S.A. management, to oversee the development of TheraCIM-hR3. Kuhnil will fund Korean development costs and provide an undisclosed amount...See full deal structure in Biomedtracker
Partners: Oncoscience AG Daiichi Sankyo Co., Ltd. InnoKeys PTE Ltd.
Additional information available to subscribers only: